Independent urology faces stagnant Medicare pay, rising costs, prior auth burden, and consolidation pressure, Celeste Kirschner, CAE, MHSA, says.
|Articles|June 1, 2007
Quality reporting: A straw man for cost cutting?
Value-based purchasing actually has little to do with outcomes in patient care, and has more to do with cost-containment in health care delivery.
Advertisement
Advertisement
Related to this article
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Advertisement
Advertisement
Trending on Urology Times
1
The Evolving Landscape of Minimally Invasive BPH Therapy
2
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
3
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
4
TURP, HoLEP, and the Future of Minimally Invasive BPH Therapy
5